RxDoctor Payments Data

Mary Scully, MD

Infectious Disease · Santa Barbara, CANPI 1487766275

Payments from drug & device makers

$93,237in general payments, 2019–2025

Across 49 payments — averaging $1902.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi Pasteur Inc.$92K
  • Viiv Healthcare Company$607
  • Gilead$327
  • AbbVie$80
  • Paratek Pharmaceuticals, Inc.$44
  • Alnylam Pharmaceuticals Inc.$23
  • plus $41 from 2 others

What the payments were for

  • Food & beverage$1,04293%
  • Education$807%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$93,237 in reported general payments places this provider in the 85th percentile of 856 infectious disease providers in California.

See all infectious disease providers in California

Medicare billing

Part B allowed, 2024
$42,984
Medicare patients
171
Services billed
305

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
DovatoDolutegravir Sodium/Lamivudine89$293,125
BiktarvyBictegrav/Emtricit/Tenofov Ala13$51,125
Atovaquone-Proguanil HclAtovaquone/Proguanil Hcl148$11,608
Meropenem27$9,167
Daptomycin17$5,379
Methenamine Hippurate43$1,875
Itraconazole20$1,712
ValacyclovirValacyclovir Hcl27$1,470
Doxycycline Hyclate36$1,268
Azithromycin209$973
Fluconazole21$816
Rifampin16$676
Ondansetron OdtOndansetron126$483
Cefadroxil16$461
Cephalexin15$236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato$607$293,12589 claims
GileadBiktarvy$327$51,12513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 856 infectious disease providers in California.

Other infectious disease in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →